New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.

@article{Bonifati1999NewSC,
  title={New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.},
  author={Vincenzo Bonifati and Giuseppe Meco},
  journal={Pharmacology & therapeutics},
  year={1999},
  volume={81 1},
  pages={1-36}
}
Levodopa remains the most effective drug for Parkinson's disease (PD). However, its benefits are limited owing to extensive metabolism by catechol-O-methyltransferase (COMT), especially if levodopa is used in combination with peripheral dopa-decarboxylase inhibitors. A new generation of potent, orally active, selective, and reversible COMT inhibitors has become available recently. Among these, tolcapone and entacapone have been best characterised. Preclinical and clinical studies have shown… CONTINUE READING
25 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…